Blog

How Medicines Are Made, Delivered, Packaged and Tested, and Why Supply Resilience Is Now a Strategic Priority

Mobility Foresights Healthcare & Life Sciences Research | Hub Analysis | September 2026

New molecules get most of the attention in pharmaceuticals, but a large share of value and risk sits in operations: the generics that fill about nine in ten U.S. prescriptions, the delivery technologies that turn a molecule into a usable medicine, the contract manufacturers that produce it, and the packaging and analytical tools that keep it safe. Several forces have moved these once back-office functions into the boardroom:

• Recurring drug shortages, with U.S. active shortages reaching a record of more than 300 in early 2024.
• Consolidation among contract manufacturers, highlighted by Novo Holdings' $16.5 billion acquisition of Catalent.
• Track-and-trace mandates, including full U.S. serialization enforcement under the Drug Supply Chain Security Act.
• Rapid growth of AI in laboratories and regulatory science.

This hub brings together 43 Mobility Foresights market studies across five areas: generics and essential medicines; drug delivery, excipients and reformulation; CDMO, fill-finish and manufacturing automation; pharmaceutical packaging and primary containers; and laboratory, R&D and pharma AI tools.

Key Takeaways

• Generic economics are under strain. Low prices concentrate production among a few suppliers, which is why sterile injectables dominate shortage lists.
• Delivery technology is a lifecycle engine. Long-acting injectables, intravesical systems and 505(b)(2) reformulations extend the value of known molecules at lower development risk.
• Fill-finish capacity is the binding constraint. Sterile fill-finish for biologics, GLP-1s and oncology drugs is the tightest link in contract manufacturing.
• Packaging is becoming a data and safety platform. Serialization, connected packaging and silicone-free polymer syringes add function beyond containment.
• AI is moving into regulated workflows. Pharmacovigilance, health technology assessment dossiers and autonomous labs are early adopters of generative and physical AI.

How We Segment Pharma Operations

1. Generics and Essential Medicines

Generics deliver most of the volume in healthcare at a small share of the cost, but prolonged price erosion has pushed many manufacturers out of low-margin products. The result is supply concentration and recurring shortages. Our small molecule generic drugs market report sizes the core oral and injectable generics market and the pricing and consolidation dynamics shaping it.

Four reports cover the shortage-prone hospital segments:

• The critical care injectable generics market study covers intensive-care drugs such as vasopressors, sedatives and electrolytes.
• The perioperative injectable generics market report covers anesthesia and surgical drugs.
• The hospital sterile supply generics market study covers the broader sterile generics that hospitals depend on daily.
• The controlled substance generics market report addresses a category where regulatory production quotas add a further constraint; stimulant shortages have persisted since 2022.

Therapeutic-area and access views complete the picture:

• The chronic disease generics market report covers cardiovascular, respiratory and other chronic-therapy generics.
• The diabetes and metabolic generics market study covers diabetes and metabolic generics, a segment set to change as GLP-1 patents begin to expire in major emerging markets.
• The neurology and psychiatry generics market report covers neurology and psychiatry generics.
• The dermatology topical generics market study covers topicals, where proving bioequivalence is technically harder and competition is thinner.
• The heat-stable essential medicines market report covers formulations that survive without cold chains in tropical and low-resource settings.
• The pharmerging market study sizes demand across China, India, Brazil and other high-growth emerging pharmaceutical markets.

2. Drug Delivery, Excipients and Reformulation

Delivery innovation lets companies improve adherence, safety and exclusivity without discovering a new molecule. Our long-acting injectable (LAI) drug delivery market report covers monthly to six-monthly injectables across psychiatry, addiction, HIV and hormonal therapy. The topical long-acting drug delivery market study covers extended-release patches, gels and implants applied to skin and mucosa.

Localized delivery is a growth niche in urology and oncology. Drug-releasing devices placed in the bladder can maintain drug exposure for weeks, a model now in late-stage development for bladder cancer. Our intravesical drug delivery system market report sizes the device and drug-device combination market. The intravesical drug delivery systems market study provides the pipeline and technology-platform view of the same field.

The regulatory route often decides the business case. The 505(b)(2) drug reformulation market report covers the U.S. pathway that allows new formulations, routes and combinations of approved drugs to rely partly on existing data, a lower-risk path to differentiated products. Three reports cover the enabling technologies:

• The 3D-printed tablets market study covers additive manufacturing of dosage forms, first approved by the FDA in 2015 for a rapidly dissolving epilepsy tablet.
• The nanoparticle drug delivery system analysis market report covers the analytical characterization of lipid and polymer nanoparticles, now a regulatory necessity for mRNA and gene-editing products.
• The next-generation excipients market study covers novel inactive ingredients, which the FDA began evaluating through a dedicated pilot program in 2021. The high-purity sugar excipients market report covers sucrose, trehalose and mannitol grades used to stabilize biologics.

3. CDMO, Fill-Finish and Manufacturing Automation

Contract development and manufacturing organizations (CDMOs) now produce a large share of the industry's products, and sterile fill-finish is where capacity is tightest. Demand from GLP-1 pens, biologics and ADCs has absorbed available lines. Three reports cover the capacity question:

• Our sterile fill-finish CDMO market report sizes the capacity, pricing and consolidation dynamics of this segment.
• The oncology biologics fill/finish CDMO market study focuses on high-potency and cytotoxic products that need specialized containment.
• The sterile API-to-fill-finish generics market report covers vertically integrated sterile generics production, a model increasingly favored by governments seeking supply resilience.

Automation and input quality are the other levers:

• The small-molecule drug product manufacturing automation market report covers continuous manufacturing, robotics and process analytics in oral solid dose production.
• The AI-driven compounding robots market study covers robotic IV compounding in hospital pharmacies, which improves sterility and dose accuracy under stricter compounding standards.
• The high-purity chemicals for life sciences market report covers the solvents, reagents and buffers whose quality and origin are now scrutinized as part of supply-chain security.

4. Pharmaceutical Packaging and Primary Containers

Packaging has regulatory, safety and increasingly digital roles. Three reports cover the safety function:

• Our child-resistant and tethered pharmaceutical packaging market report covers closures that prevent accidental ingestion and keep caps attached.
• The pharmaceutical safety packaging market study covers tamper evidence and anti-counterfeiting features required under U.S. and EU serialization rules.
• The connected and smart pharmaceutical packaging market report covers packs with NFC, sensors or dose tracking that feed adherence data to patients, pharmacists and trial sponsors.

Four reports cover primary containers and patient-facing formats:

• The patient-centric drug packaging market report covers easy-open, calendarized and accessible designs for older patients and self-administration.
• The biologics and specialty drug packaging market study covers vials, cartridges, prefilled syringes and autoinjector components for high-value biologics.
• The silicone-free syringes market report covers syringes that avoid the silicone-oil droplets that can interact with sensitive biologics and ophthalmic drugs.
• The ready-to-fill polymer syringe market study covers cyclic olefin polymer and copolymer syringes supplied sterile and ready to fill, which reduce breakage and suit high-value drugs.

5. Lab, R&D Tools and Pharma AI

Drug discovery is shifting toward human-relevant cell models and data-rich imaging. The FDA Modernization Act 2.0 (2022) removed the statutory animal-testing requirement, and the FDA set out a 2025 roadmap to reduce animal testing for antibodies. Four reports cover the tools behind this shift:

• Our immortalized cell line market report covers the cell lines used in discovery, toxicology and biologics production.
• The live cell imaging instruments and consumables market study covers the systems that track cellular behavior over time.
• The high-content imaging and phenotypic screening market report covers automated imaging that measures many cellular features at once, increasingly analyzed with AI.
• The fluorometer market and LED stereo microscope market reports cover core laboratory instruments.

Analytical and quality tools are the second group. The centrifugal field-flow fractionation system market report covers a separation technique used to characterize nanoparticles, viruses and protein aggregates. The Raman spectroscopy in counterfeit drug detection market study covers handheld and laboratory Raman systems. These matter because the WHO has estimated that around one in ten medical products in low- and middle-income countries is substandard or falsified.

AI is entering regulated pharmaceutical workflows:

• The AI-driven drug safety and pharmacovigilance platforms market report covers automated adverse-event case processing and signal detection.
• The generative AI in health technology assessment (HTA) market study covers AI-assisted evidence synthesis and dossier preparation as HTA bodies publish guidance and EU joint clinical assessments begin.
• The physical AI scientists market report covers autonomous, robot-run laboratories that design and execute experiments in closed loops.

Where Value Is Created: The Pharma Operations Value Chain

Regional perspective

• United States. The largest generics and CDMO market, where shortage policy, domestic manufacturing incentives and proposed biotech supply-chain legislation are reshaping sourcing.
• Europe. Strong in sterile manufacturing, packaging and serialization, with EU pharmaceutical legislation reforms aimed at shortage prevention.
• India. A major exporter of generic drugs and APIs and a growing CDMO destination as buyers diversify supply.
• China. A dominant supplier of key starting materials and APIs; diversification away from single-source dependence is a multi-year process.

What to Watch Through 2032

1. Sterile capacity additions: new fill-finish lines, and whether they relieve shortages or are absorbed by GLP-1 and biologic demand.
2. Supply-chain policy: onshoring incentives, stockpiling and biotech supply-chain legislation will shift where generics and APIs are made.
3. Long-acting and localized delivery approvals: these will test the value of formulation-led differentiation.
4. AI validation standards: regulator guidance will determine how fast AI moves into pharmacovigilance and submissions.
5. Non-animal testing adoption: this will drive demand for cell-based models and high-content imaging.

Frequently Asked Questions

Why do drug shortages mostly affect generic injectables?

Sterile injectables are complex to make, sold at low prices and often produced by few suppliers, so a single quality problem or plant disruption can remove a large share of supply. Low margins discourage new capacity.

What is a 505(b)(2) application?

It is a U.S. regulatory pathway that allows a new formulation, dose, route or combination of an approved drug to rely partly on existing safety and efficacy data, reducing development time and cost compared with a new chemical entity.

Why is sterile fill-finish capacity so constrained?

Biologics, GLP-1 pens, vaccines and oncology drugs all require aseptic filling on specialized lines that take years to build and qualify. Rapid demand growth has absorbed available capacity at contract manufacturers.

What are long-acting injectables used for?

Long-acting injectables release a drug over weeks or months. They are widely used in schizophrenia, opioid-use disorder, HIV and hormonal therapy, where daily adherence is difficult.

Why are polymer and silicone-free syringes growing?

Polymer syringes resist breakage and can be supplied ready to fill, while silicone-free designs avoid silicone-oil particles that can affect sensitive biologics and ophthalmic drugs.

How is AI used in pharmacovigilance?

AI tools automate adverse-event intake, coding and case processing and help detect safety signals in large datasets, reducing manual workload while regulators define validation expectations.

What do Mobility Foresights pharma operations reports include?

Each linked report provides market size and multi-year forecasts, growth drivers and challenges, segmentation by product, application and region, competitive landscape and company profiles, and recent developments. Customization is available on request.

Work With Mobility Foresights

Mobility Foresights provides syndicated and custom research on generics, drug delivery, contract manufacturing, packaging and pharmaceutical R&D tools. Each report linked above can be purchased individually or tailored to a specific product, region or sourcing question. Related analysis is available in our oncology and hematology therapeutics landscape. To request a sample or commission a bespoke study, contact our healthcare research team.